Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H8O4 |
Molecular Weight | 180.1574 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OC1=C(C=CC=C1)C(O)=O
InChI
InChIKey=BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
Molecular Formula | C9H8O4 |
Molecular Weight | 180.1574 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18543581
Curator's Comment: The penetration of the blood-brain barrier was studied in animals.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11124191
Curator's Comment: Felix Hoffmann discovered aspirin when working for Friedrich Bayer & Co. # Bayer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) |
1.2 µM [IC50] | ||
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) |
5.2 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SYNALGOS-DC Approved UseSYNALGOS-DC is a combination of dihydrocodeine, an opioid agonist, aspirin, a nonsteroidal anti-inflammatory drug, and caffeine, a methylxanthine, and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date-3.62620813E11 |
|||
Primary | FIORINAL Approved UseFIORINAL is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fiorinal in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Launch Date2.00016003E11 |
|||
Preventing | DURLAZA Approved UseDURLAZA is a nonsteroidal anti-inflammatory drug indicated to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina and to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack. Launch Date1.44132486E12 |
|||
Preventing | AGGRENOX Approved UseAGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Launch Date9.4322878E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
54.25 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.84 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.31 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.12 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.322 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.422 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/24672263 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ASPIRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
68% |
ASPIRIN plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Sources: https://www.karger.com/Article/Abstract/321727 Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Sources: https://dmd.aspetjournals.org/content/42/6/996.short Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11205285/ Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
no | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
no | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 1242 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 2337 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 278.6 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 40.7 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 683.1 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 698.2 uM] | |||
Sources: https://dmd.aspetjournals.org/content/34/2/199.short Page: - |
yes [Km 94.2 uM] | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Acetyl salicylic acid improves somatosensory evoked potentials in streptozotocin-diabetic rats. | 1999 Dec |
|
[Salicylism and glaucoma: reciprocal augmentation of the toxicity of acetazolamide and acetylsalicylic acid]. | 1999 Feb |
|
Statins and peripheral neuropathy. | 1999 Jan |
|
Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. | 1999 Jun 28 |
|
Sulindac inhibits activation of the NF-kappaB pathway. | 1999 Sep 17 |
|
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. | 2000 Aug |
|
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine]. | 2000 Jul |
|
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. | 2000 Jun 16 |
|
Aspirin-associated intracerebral hemorrhage: clinical and radiologic features. | 2000 Jun 27 |
|
Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. | 2001 Feb |
|
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. | 2001 Feb |
|
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. | 2001 Feb 2 |
|
Addition of hydrophilic and lipophilic compounds of biological relevance to the monoolein/water system. I. Phase behavior. | 2001 Jan |
|
Present treatment options for unstable angina and non-Q-wave myocardial infarction. | 2001 Jan |
|
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. | 2001 Jan |
|
Antithrombotic therapy in atrial fibrillation. | 2001 Jan |
|
The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. | 2001 Jan |
|
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols. | 2001 Jan |
|
Endogenous nitric oxide and prostaglandins synergistically counteract thromboembolism in arterioles but not in venules. | 2001 Jan |
|
Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. | 2001 Jan |
|
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. | 2001 Jan |
|
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | 2001 Jan |
|
Salicylate and cocaine: interactive toxicity during chicken mid-embryogenesis. | 2001 Jan 15 |
|
Authors' reply on aspirin for primary prevention. | 2001 Jan 20 |
|
Pharmacological properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-. | 2001 Jan 5 |
|
Drug Points: tachycardia associated with moxifloxacin. | 2001 Jan 6 |
Sample Use Guides
Severe pain: Initiate treatment with two capsules (1 capsule contains 16 mg dihydrocodeine bitartrate, 356.4 mg aspirin, and 30 mg caffeine) orally every 4 hours as needed for pain. Headache: One or 2 capsules (1 capsule contains 50 mg butalbital, 325 mg aspirin and 40 mg caffeine) every 4 hours. Total daily dose should not exceed 6 capsules. Prevention of stoke and heart attacks: the recommended dose is one capsule of aspirin (162.5 mg) once daily. Take the capsules with a full glass of water at the same time each day. Prevention of stroke (in combination with dipyridamole): the recommended dose is one capsule (200 mg dipyridamole and 25 mg aspirin) given orally twice daily.
Route of Administration:
Enteral
Human platelet-rich plasma was incubated with various aspirin concentrations (10, 20, 50, 100, 200, 300, 400, 500 uM) at 37C for up to 4.5 h. Platelet aggregation and thromboxane generation were measured. Inhibition of platelet aggregation and thromboxane formation by 10 uM aspirin was maximal by 90 min. There was progressive inhibition by 3 uM aspirin during incubation for 270 min. By the end of this time there was also significant inhibition by 1 uM aspirin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:52:25 UTC 2022
by
admin
on
Fri Dec 16 16:52:25 UTC 2022
|
Record UNII |
R16CO5Y76E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C07FX02
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
CFR |
21 CFR 343.13
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
CFR |
21 CFR 343.12
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QN02BA51
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C10BX01
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QB01AC56
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
LIVERTOX |
NBK548900
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C10BX05
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
A01AD05
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QM01BA03
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DUOCOVER (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
M01BA03
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
FDA ORPHAN DRUG |
724719
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C10BX04
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL/ACETYLSALICYLIC ACID (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL/ACETYLSALICYCLIC ACID (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02AJ02
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
FDA ORPHAN DRUG |
764120
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QN02BA71
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QB01AC06
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DUOPLAVIN (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QC10BX05
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
NDF-RT |
N0000008836
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
NDF-RT |
N0000000160
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DUOPLAVIN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.5
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
NDF-RT |
N0000008836
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02BA71
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02BA01
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
FDA ORPHAN DRUG |
724619
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QC10BX02
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
FDA ORPHAN DRUG |
607917
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C10BX08
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
CFR |
21 CFR 520.1409
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
B01AC08
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
B01AC56
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EU-Orphan Drug |
EU/3/04/208
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02BA51
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
B01AC06
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C10BX06
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02BA15
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QA01AD05
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C10BX02
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C10BX12
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
NDF-RT |
N0000175578
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02AJ07
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QC10BX01
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02AJ18
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EPA PESTICIDE CODE |
129061
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
7.1
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
2.1
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
CFR |
21 CFR 341.40
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C07FX03
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
C07FX04
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QN02BA01
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DUOCOVER (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-VATC |
QC10BX04
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
||
|
WHO-ATC |
N02BA65
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00945
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
1044006
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
D001241
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
R16CO5Y76E
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
200-064-1
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
2244
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
C287
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
R16CO5Y76E
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
652
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
1191
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
50-78-2
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
74
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
91101
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
ALTERNATIVE | |||
|
SUB12730MIG
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
M2111
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | Merck Index | ||
|
4139
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
ASPIRIN
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
ASPIRIN
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless or almost odourless. Solubility: Soluble in about 300 parts of water; freely soluble in ethanol (~750 g/l) TS; soluble in ether R. Category: Analgesic; antipyretic. Storage: Acetylsalicylic acid should be kept in a tightly closed container, protected from light. Additional information: Even in the absence of light, Acetylsalicylic acid is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Acetylsalicylic acid contains not less than 99.0% and not more than 100.5% of C9H8O4, calculated with reference to the dried substance. | ||
|
27223
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
15365
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
Aspirin
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
CHEMBL25
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
406186
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY | |||
|
DTXSID5020108
Created by
admin on Fri Dec 16 16:52:26 UTC 2022 , Edited by admin on Fri Dec 16 16:52:26 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
URINE
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
IDENTIFIED AS IMPURITY E
Limits: impurity E: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)Herbal Medicines 4th ED 2103
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
IDENTIFIED AS IMPURITY A
Limits: impurity A: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
ASSAY (COLORIMETRIC)
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
IDENTIFIED AS IMPURITY B
Limits: impurity B: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.15 per cent)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|